亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Methods of Tissue Repair, Regeneration, and Tissue Engineered Compositions

技術應用
Potential uses of pleiotrophin and related factors include: Kidney growth, morphogenesis, and regeneration in vivo and ex vivo. In vitro engineering of nephrons and artificial kidneys from kidney progenitor cells and embryonic tissues.Repair and regeneration of the injured kidney (eg. acute tubular necrosis from ischemic or toxic insult).Protection and growth of tissue for transplantation.Treatment of chronic kidney by gene therapy or other method of administration.
詳細技術說明
Scientists at UC San Diego have developed a method of propagating ureteric bud (UB) cells in culture under conditions that induce the UB to undergo branching morphogenesis in order to generate a population of UB comprising tubular branches, subdividing the UB population, and resuspending each subpopulation in culture media. They have isolated an epithelial ureteric bud branching morphogenetic activity from the metanephric mesenchyme-derived cell conditioned medium and identified one of such molecules as an 18 kDa heparin binding protein, pleiotrophin. The invention demonstrates that purified pleiotrophin induces impressive branching morphogenesis of the isolated UB in vitro and provides methods of using pleiotrophin and compositions comprising pleiotrophin or other factors in the conditioned medium to induce morphogenesis in the kidney cells in vitro and in vivo. Additionally, methods and compositions are provided for constructing stable mammalian embryonic epithelial tissues and organs as well as constructing kidney tissue and treating renal failure.
*Abstract
End-stage renal disease (ESRD) affects almost 350,000 people living in the United States with an incidence that has increased by over 50 percent in the past decade.  The two current treatment modalities for ESRD, dialysis and transplantation, both have significant limitations. Patients on dialysis have an extremely high mortality rate, approaching 20 percent per year. Although patient survival is markedly improved with renal transplantation, the number of renal transplants is severely limited by the short supply of available organs and many patients die while awaiting transplantation of a kidney allograft. Recently, several alternative modalities have been proposed  including augmentation of traditional hemodialysis with a "renal assist device," xenotranplantation of whole developing kidney rudiments into adults, and the generation of histocompatible renal tissue using nuclear transplantation techniques.
*IP Issue Date
Feb 5, 2008
*Principal Investigation

Name: Kevin Bush

Department:


Name: Sanjay Nigam

Department:


Name: Hiroyuki Sakurai

Department:

附加資料
Patent Number: US7326570B2
Application Number: US2003608783A
Inventor: Nigam, Sanjay Kumar | Sakurai, Hiroyuki | Bush, Kevin T.
Priority Date: 16 Jun 2000
Priority Number: US7326570B2
Application Date: 27 Jun 2003
Publication Date: 5 Feb 2008
IPC Current: A61K003818 | C12N0005071
US Class: 435369 | 4240931 | 4240937 | 435325 | 435375 | 435395 | 435405
Assignee Applicant: The Regents of the University of California
Title: Induction of tubular morphogenesis using pleiotrophin
Usefulness: Induction of tubular morphogenesis using pleiotrophin
Summary: (M1) is useful for propagating uteric bud (UB) cells in culture. (IV) is useful for treating a subject suffering from kidney failure, which involves transplanting (IV) into the subject. (I)-(IV) is useful for transplantation into a subject, where the tissue is implanted into a subject for the purpose of regeneration, due to ischemic or toxic insult or for the purpose of protection and growth of the tissue. (M10) is useful for treating acute renal failure (claimed).
Novelty: Propagating uteric bud (UB) cells in culture, by culturing UB in vitro to induce UB to undergo branching morphogenesis to generate UBs comprising tubular branches and subdividing UBs, resuspending UBs in media and repeating culturing
主要類別
診斷/治療
細分類別
其他疾病
申請號碼
7326570
其他

Additional Technologies by these Inventors


Tech ID/UC Case

19692/2001-205-0


Related Cases

2001-205-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備